Effect of Fermentable Carbohydrate on Glucose Homeostasis

NCT01841073 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-11-25

Study results available
· View outcomes & findings →

Summary

The rise in the prevalence of type 2 diabetes is related to recent lifestyle changes leading to a rise in obesity. Obesity is a risk factor for Impaired Glucose Tolerance (IGT) and diabetes. A type of fibre - fermentable carbohydrate - may help prevent diabetes in individuals with IGT by reducing appetite and food intake, and improving insulin sensitivity. Although fermentable carbohydrate is not absorbed in the small intestine it is full fermented by the colonic bacteria. The fermentation of this carbohydrate produces short chain fatty acids which act on specific G protein coupled receptors (GPR41/43) in the intestine to release GLP-1 and PYY. GLP-1 and PYY are hormones which act on appetite centres in the brain to decrease appetite. GLP-1 incretin effects and possible effect of the beta cell will increase insulin sensitivity. Short chain fatty acids also suppress the release of free fatty acids from adipocytes. Lower levels of free fatty acids in insulin resistant subject's leads to improved insulin sensitivity. This body of work will examine the effect of fermentable carbohydrate on appetite, weight loss, blood glucose control which will give an indication of the possibility of fermentable carbohydrate to prevent type 2 diabetes in this at-risk group.

Conditions

Interventions

DIETARY_SUPPLEMENT

Inulin

Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.

DIETARY_SUPPLEMENT

Cellulose

Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.

DIETARY_SUPPLEMENT

Inulin

Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle. Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.

DIETARY_SUPPLEMENT

Cellulose

Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle. Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.

DIETARY_SUPPLEMENT

Inulin

Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.

DIETARY_SUPPLEMENT

Cellulose

Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Gary Frost, PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-08-31
Completion
2014-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841073 on ClinicalTrials.gov